These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23553447)

  • 1. Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire.
    de Vries ST; Mol PG; de Zeeuw D; Haaijer-Ruskamp FM; Denig P
    Drug Saf; 2013 Sep; 36(9):765-77. PubMed ID: 23553447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study.
    de Vries ST; Haaijer-Ruskamp FM; de Zeeuw D; Denig P
    Health Qual Life Outcomes; 2014 Aug; 12():103. PubMed ID: 25115618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validity of a patient-reported adverse drug event questionnaire using different recall periods.
    de Vries ST; Haaijer-Ruskamp FM; de Zeeuw D; Denig P
    Qual Life Res; 2014 Nov; 23(9):2439-45. PubMed ID: 24848596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study.
    Brajovic S; Blaser DA; Zisk M; Caligtan C; Okun S; Hall M; Pamer CA
    JMIR Med Inform; 2018 Aug; 6(3):e42. PubMed ID: 30131314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
    Sonawane KB; Cheng N; Hansen RA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for assessing the preventability of adverse drug events: a systematic review.
    Hakkarainen KM; Andersson Sundell K; Petzold M; Hägg S
    Drug Saf; 2012 Feb; 35(2):105-26. PubMed ID: 22201475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a computer-based adverse-drug-event monitor.
    Hwang SH; Lee S; Koo HK; Kim Y
    Am J Health Syst Pharm; 2008 Dec; 65(23):2265-72. PubMed ID: 19020194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug events in older hospitalized patients: results and reliability of a comprehensive and structured identification strategy.
    Klopotowska JE; Wierenga PC; Stuijt CC; Arisz L; Dijkgraaf MG; Kuks PF; Asscheman H; de Rooij SE; Lie-A-Huen L; Smorenburg SM;
    PLoS One; 2013; 8(8):e71045. PubMed ID: 23940688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A targeted method for standardized assessment of adverse drug events in surgical patients.
    de Boer M; Kiewiet JJ; Boeker EB; Ramrattan MA; Dijkgraaf MG; Lie-A-Huen L; Boermeester MA;
    J Eval Clin Pract; 2013 Dec; 19(6):1073-82. PubMed ID: 23593984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug event reporting systems: a systematic review.
    Bailey C; Peddie D; Wickham ME; Badke K; Small SS; Doyle-Waters MM; Balka E; Hohl CM
    Br J Clin Pharmacol; 2016 Jul; 82(1):17-29. PubMed ID: 27016266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool.
    Hébert G; Netzer F; Ferrua M; Ducreux M; Lemare F; Minvielle E
    Eur J Cancer; 2015 Feb; 51(3):427-35. PubMed ID: 25549531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital.
    Carnevali L; Krug B; Amant F; Van Pee D; Gérard V; de Béthune X; Spinewine A
    Ann Pharmacother; 2013 Nov; 47(11):1414-9. PubMed ID: 24285758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes.
    Cragg A; Small SS; Lau E; Rowe A; Lau A; Butcher K; Hohl CM
    Drug Saf; 2023 Nov; 46(11):1161-1172. PubMed ID: 37783974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of different data sources in identifying adverse drug events in hospitalized patients.
    Egbring M; Far E; Knuth A; Roos M; Kirch W; Kullak-Ublick GA
    Eur J Clin Pharmacol; 2011 Sep; 67(9):909-18. PubMed ID: 21394526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital admissions caused by adverse drug events: an Australian prospective study.
    Phillips AL; Nigro O; Macolino KA; Scarborough KC; Doecke CJ; Angley MT; Shakib S
    Aust Health Rev; 2014 Feb; 38(1):51-7. PubMed ID: 24351707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report.
    Jha AK; Kuperman GJ; Teich JM; Leape L; Shea B; Rittenberg E; Burdick E; Seger DL; Vander Vliet M; Bates DW
    J Am Med Inform Assoc; 1998; 5(3):305-14. PubMed ID: 9609500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of International Classification Of Diseases, 9th Revision, Clinical Modification codes as an adverse drug event surveillance system.
    Hougland P; Xu W; Pickard S; Masheter C; Williams SD
    Med Care; 2006 Jul; 44(7):629-36. PubMed ID: 16799357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.
    Gavaza P; Brown CM; Khoza S
    Pharm World Sci; 2010 Oct; 32(5):651-7. PubMed ID: 20652830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detecting adverse drug events during the hospital stay].
    Berga Culleré C; Gorgas Torner MQ; Altimiras Ruiz J; Tuset Creus M; Besalduch Martín M; Capdevila Sunyer M; Torres Gubert M; Casajoana Cortinas MT; Baró Sabaté E; Fernández Solà JR; Moron i Besolí A; Odena Estradé E; Serrais Benavente J; Vitales Farrero MT; Codina Jané C
    Farm Hosp; 2009; 33(6):312-23. PubMed ID: 20038390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and reliability of clinical coding surveillance for the routine monitoring of adverse drug events in New Zealand hospitals.
    Ng J; Andrew P; Muir P; Greene M; Mohan S; Knight J; Hider P; Davis P; Seddon M; Scahill S; Harrison J; Zhou L; Selak V; Lawes C; Galgali G; Broad J; Crawley M; Pevreal W; Houston N; Brott T; Ryan D; Peach J; Brant A; Bramley D
    N Z Med J; 2018 Oct; 131(1484):46-60. PubMed ID: 30359356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.